Reveal LINQ Respiration Clinical Study
Reveal LINQ Respiration Clinical Study
The LINQ™ Respiration study will collect and characterize Reveal LINQ™ derived respiration
 data from patients undergoing a simulated 24-hour time period while being monitored with
 capnography.
The Reveal LINQ™ Respiration study is a Non-Significant Risk IDE, observational,
 non-randomized, multi-center, clinical study. The study is expected to be conducted at up to
 5 centers in the United States and up to 100 subjects will be enrolled, with no more than 25
 subjects enrolled per site. In addition, a minimum of 30% of all enrolled subjects will have
 a history of heart failure.

 All enrolled subjects will either have the investigational LINQ HF or ALLEVIATE-HF RAMware
 downloaded onto their implanted Reveal LINQ device, Holter monitor and capnography monitor
 applied and undergo a series of activity and breathing maneuvers. The expected duration of
 subject participation in the study (from start of study procedures to study exit) is
 approximately 1.5 hours. The expected total study duration (from time of first enrollment to
 the exit of last enrolled subject) is approximately 3 months.

 All Adverse events will be collected throughout the study duration of a subject's
 participation in the study, beginning at the time of informed consent.
Inclusion Criteria:

 -  Patient is ≥ 55 years old

 -  Patient (or patient's legally authorized representative) is willing and able to
 provide written informed consent

 -  Patient is willing and able to comply with the study procedures

 -  Patient has an active Medtronic Reveal LINQ device that has been implanted for ≥ 60
 days and no more than 3 years

 Exclusion Criteria:

 -  Patient has an existing condition that necessitates the use of supplemental oxygen

 -  Patient has an active acute respiratory infection or a respiratory disorder that may
 affect ability to perform respiratory maneuvers

 -  Patient has NYHA Class IV heart failure per most recent assessment

 -  Any concomitant condition that might endanger the patient through participation in the
 study or interfere with study procedures, as assessed by the investigator

 -  Patient is enrolled in another study that could confound the results of this study

 -  Patient has an existing implantation of Medtronic IPG, ICD, CRT-D or CRT-P device